Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression

American Journal of Transplantation

Volumn 11, Issue 11, 2011, Pages 2379-2387

  McKenna, G J ^a   Trotter, J F ^a   Klintmalm, E ^a   Onaca, N ^a   Ruiz, R ^a   Jennings, L W ^a   Neri, M ^a   O'Leary, J G ^a   Davis, G L ^a   Levy, M F ^a   Goldstein, R M ^a   Klintmalm, G B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fibrosis; Hepatitis C virus; Liver transplantation; MTOR inhibitor inhibition; Sirolimus

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; INTERFERON; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 83555164165     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03767.x     Document Type: Article

References (18)

1. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibitis spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 2833-2836.
2. Blecker E, De Gottardi A, Neef M, et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: Analysis of the underlying mechanisms. J of Pharm Exp Thera 2005; 313: 951-962.
3. Neef M, Ledermann M, Saegesser H, Scheider V, Reichen J. Lowdose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatology 2006; 45: 786-796. (Pubitemid 44646687)
4. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340. (Pubitemid 28385231)
5. Shegogue D, Trojanowksa M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Bio Chem 2004; 279: 23166-23175. (Pubitemid 38685622)
6. Bongeio RGB, Fuhro R, Wang Z, et al. Rapamycin amerliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072. (Pubitemid 41716437)
7. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 2009; 87: 1290-1299.
8. Pontrelli P, Rossini M, Infante B, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125-134.
9. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341-1350.
10. Ishida H, Li K, Yi M, Lemon SM. P21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem 2007; 282: 11836-11848 (Pubitemid 47100711)
11. Shao RX, Zhang L, Peng LF, et al. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol 2010; 84: 6060-6069.
12. Peng L, Liang D, Tong W, Li J, Yuan Z. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 2010; 285: 20870-20881.
13. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262. (Pubitemid 41061075)
14. Ballardhini G, De Raffele E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted HCVinfected liver. Liver Transpl 2002; 8: 10-20. (Pubitemid 34092667)
15. Gane EJ, Naoumov N, Qian K, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177. (Pubitemid 26021616)
16. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14: S36-S44.
17. Firpi RJ, Abdelmalek MF, Soldevilo-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247. (Pubitemid 39406077)
18. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatology 2004; 41: 830-836. (Pubitemid 39434314)